Kyverna Therapeutics, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- Kyverna Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 8.75, a 64.40% increase year-over-year.
- Kyverna Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 7.97, a 9.32% increase year-over-year.
- Kyverna Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 7.65, a 9.66% decline year-over-year.
- Kyverna Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 5.05, a 51.32% decline year-over-year.
- Kyverna Therapeutics, Inc. quick ratio for fiscal 2025 was 7.65, a 9.66% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. quick ratio for fiscal 2024 was 8.47, a 192.38% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. quick ratio for fiscal 2023 was 2.9.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |